Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Feb;9(2):158-159.
doi: 10.1158/2159-8290.CD-NB2018-169. Epub 2018 Dec 12.

T-DM1 Reduces HER2+ Breast Cancer Recurrence

No authors listed
Comment

T-DM1 Reduces HER2+ Breast Cancer Recurrence

No authors listed. Cancer Discov. 2019 Feb.

Abstract

Findings from the phase III KATHERINE trial show that patients with residual HER2+ breast cancer after neoadjuvant treatment are half as likely to develop invasive disease recurrence if they are treated with T-DM1 instead of trastuzumab, the current standard of care.

PubMed Disclaimer

Comment on

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
    von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.